Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). PolyPeptide Group AG's share price for the quarter that ended in Dec. 2023 was CHF17.52. PolyPeptide Group AG's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 33.0 Mil. Therefore, PolyPeptide Group AG's market cap for the quarter that ended in Dec. 2023 was CHF577.6 Mil.
PolyPeptide Group AG's quarterly market cap
declined
from Dec. 2022 (CHF833.7 Mil) to Jun. 2023 (CHF618.4 Mil) and
declined
from Jun. 2023 (CHF618.4 Mil) to Dec. 2023 (CHF577.6 Mil).
PolyPeptide Group AG's annual market cap
declined
from Dec. 2021 (CHF4,535.3 Mil) to Dec. 2022 (CHF833.7 Mil) and
declined
from Dec. 2022 (CHF833.7 Mil) to Dec. 2023 (CHF577.6 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. PolyPeptide Group AG's Enterprise Value for Today is CHF1,112.3 Mil.
PolyPeptide Group AG Market Cap Historical Data
The historical data trend for PolyPeptide Group AG's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of PolyPeptide Group AG's Market Cap
For the Drug Manufacturers - Specialty & Generic subindustry, PolyPeptide Group AG's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PolyPeptide Group AG's Market Cap Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PolyPeptide Group AG's Market Cap distribution charts can be found below:
* The bar in red indicates where PolyPeptide Group AG's Market Cap falls into.
PolyPeptide Group AG Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
PolyPeptide Group AG's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PolyPeptide Group AG (XSWX:PPGN) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
PolyPeptide Group AG Market Cap Related Terms
Thank you for viewing the detailed overview of PolyPeptide Group AG's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
PolyPeptide Group AG (XSWX:PPGN) Business Description
PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives a majority of its revenue from Europe and Asia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XSWX:PPGN has been successfully added to your 